<DOC>
	<DOCNO>NCT01342653</DOCNO>
	<brief_summary>Implementation curative strategy treatment peritoneal carcinomatosis gastric cancer . The goal get 1C level evidence ( patient die `` standard '' treatment , treatment survive ) term disease free survival overall survival . Methodology : prospective , phase II , multicentric Spain . Recruitment 50 patient ( 31 treatment ) three year . This strategy base neoadjuvant systemic plus simultaneous intraperitoneal intravenous chemotherapy ( NIPS ) , treat peritoneal disease bi-directional approach ; next step cytoreductive surgery HIPEC . Once patient discharge , follow systemic adjuvant chemotherapy protocol .</brief_summary>
	<brief_title>Clinical Trial Neoadjuvant Peritoneal Systemic Chemotherapy Plus HIPEC Gastric Carcinomatosis</brief_title>
	<detailed_description>Patients peritoneal carcinomatosis gastric cancer meet inclusion criterion ( none exclusion ) follow next treatment scheme ( 40 week period treatment ) : Phase I ( one week peritoneal catheter implant ; total treatment 5-8 week ) : intraperitoneal infusion Docetaxel ( 30 mg/m2 ) Cisplatin ( 30mg/m2 ) 1000 cc saline . Intravenous administration 5-FU ( 200 mg/m2/Day , 7 day week 2 week ) simultaneously 2 cycle Intraperitoneal administration . These patient receive four six cycle NIPS . Until phase II 4-6 week . Phase II : cytoreduction ( CR ) plus HIPEC ( total treatment 4 week ) . Maximal effort optimum cytoreduction . HIPEC : intraperitoneal administration : Mytomicin C ( 15mg/m2 ) plus Adriamycin ( 15mg/m2 ) 42-43ÂºC 60 minute . Intravenous simultaneously administration 5-FU ( 400mg/m2 ) plus Leucovorin ( 20mg/m2 ) 10 minute begin peritoneal perfusion . Phase III : adjuvant chemotherapy 8-12 week surgery . Those case reach optimum cytoreduction ( CC0 ) treat systemic chemotherapy : First day : Docetaxel ( 75 mg/m2 ) Cisplatin ( 75mg/m2 ) . Days 1-5 : 5-FU ( 750mg/m2/d ) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Men woman age 1865 year old Histological Evidence peritoneal carcinomatosis gastric cancer No distance metastasis ECOG 012 No contraindication complex surgery malign disease except skin cancer ( different melanoma cervix cancer CIN III ) willing consent sign ICF . No Histological Evidence peritoneal carcinomatosis gastric cancer Previous Gastrectomy due gastric cancer . Patients gastric cancer previous systemic chemotherapy Peritoneal recurrence due gastric cancer . Distance metastasis SP &gt; 2 recruitment SP &gt; 1 surgery previous radiotherapy treatment pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Peritoneal</keyword>
	<keyword>Carcinomatosis</keyword>
	<keyword>Gastric</keyword>
	<keyword>Cancer</keyword>
	<keyword>NIPS</keyword>
	<keyword>HIPEC</keyword>
</DOC>